Anti-Human CD52 (Alemtuzumab) – HRP
Anti-Human CD52 (Alemtuzumab) – HRP
Product No.: LT202
Product No.LT202 Clone Campath-1H Target CD52 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names HE5; CDW52; EDDM5 CDW52; Cambridge pathology 1 antigen Isotype Human IgG1κ Applications ELISA , FA , FC |
Antibody DetailsProduct DetailsReactive Species Cynomolgus Monkey ⋅ Rhesus Monkey ⋅ Human Host Species Human Expression Host HEK-293 Cells FC Effector Activity Active Immunogen Human lymphocytes. Product Concentration 0.5 mg/ml Formulation This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase) Storage and Handling This horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2893940 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Alemtuzumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Additional Applications Reported In Literature ? FA ELISA Additional Reported Applications For Relevant Conjugates ? CyTOF® WB Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Alemtuzumab. Clone Campath-1H recognizes human CD52. This product is for research use only. Background Clone Campath-1H is a monoclonal antibody that specifically binds to CD52, a protein present on the surface of mature lymphocytes. However, this protein is not present on the stem cells that generated these lymphocytes. Alemtuzumab is targets and destroys mature lymphocytes containing CD-52, and is used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. Anti-Human CD52 (Alemtuzumab) utilizes the same variable regions from the therapeutic antibody Alemtuzumab making it ideal for research projects. Antigen Distribution CD52 is primarily expressed on the surface of mature lymphocytes. Additionally, CD52 is present on most lymphoid derived malignancies. However, variable expression on Myeloma cells should be noted. PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. The use of research-grade Alemtuzumab biosimilars as calibration standards or reference controls in a pharmacokinetic (PK) bridging ELISA involves several key steps and considerations: Calibration Standards Preparation
Assay Design and Execution
Use in Pharmacokinetic Studies
By employing these methods, researchers can confidently use Alemtuzumab biosimilars as calibration standards to support PK studies and ensure the equivalent efficacy and safety of biosimilar drugs compared to their reference counterparts. Biopharma companies typically perform a wide range of analytical assays to confirm the structural and functional similarity of a proposed biosimilar to the originator drug. These analytical assays are crucial for establishing the comparability of the biosimilar, which is essential for regulatory approval. Here's a breakdown of the typical analytical assays used: Structural Analytical Assays
Functional Analytical Assays
Leinco Biosimilar RoleThe query does not provide specific information about how Leinco biosimilars are used in these studies. However, in general, biosimilars like those from Leinco would undergo the same rigorous testing as any other biosimilar, focusing on demonstrating structural and functional similarity to their respective originator drugs. Regulatory and Quality Control ConsiderationsThe choice of assays is guided by regulatory considerations, such as those outlined in ICH Q6B. It is essential to use orthogonal methods—multiple complementary techniques—to ensure comprehensive characterization and to mitigate any uncertainties arising from minor differences in structure or function. The analytical similarity assessment must also include a rigorous comparison of purity and impurity profiles to ensure consistency with the originator product. Overall, the analytical assays used in biosimilar development are designed to provide a robust basis for demonstrating similarity and ensuring that the biosimilar is safe and effective for clinical use. References & CitationsTechnical ProtocolsCertificate of Analysis |
Formats Available
Prod No. | Description |
---|---|
LT200 | |
LT203 | |
LT204 | |
LT202 | |
LT201 | |
LT211 | |
LT206 | |
LT205 | |
LT207 |
